

1 **Disruption of CXCR6 Ameliorates Kidney Inflammation and Fibrosis in**
2 **Deoxycorticosterone Acetate/Salt Hypertension**

3 **Supplemental Material**

4 Yuanbo Wu^{1,2}, Changlong An³, Xiaogao Jin¹, Zhaoyong Hu¹, and Yanlin Wang^{1,3,4,5,6*}

5 ¹ Section of Nephrology, Department of Medicine, Baylor College of Medicine,
6 Houston, Texas, USA

7 ² Department of Anesthesiology, Hubei Cancer Hospital, Hubei, Wuhan, China

8 ³ Division of Nephrology, Department of Medicine, University of Connecticut School of
9 Medicine, Farmington, Connecticut, USA

10 ⁴ Department of Cell Biology, University of Connecticut School of Medicine,
11 Farmington, Connecticut, USA

12 ⁵ Institute for Systems Genomics, University of Connecticut School of Medicine,
13 Farmington, Connecticut, USA

14 ⁶ Renal Section, Veterans Affairs Connecticut Healthcare System, West Haven,
15 Connecticut, USA

16 Running Title: CXCR6 in deoxycorticosterone acetate/salt hypertension

17 *Corresponding author:

18 Yanlin Wang, MD, PhD

19 Division of Nephrology/Department of Medicine

20 University of Connecticut School of Medicine

21 263 Farmington Avenue


22 Farmington, CT 06030-1405

23 Email: yanlwang@uchc.edu

24

25 **Figure S1. Disruption of CXCR6 reduces α -SMA protein expression in the kidney.**

26 **A.** Representative Western blots show the protein levels of α -SMA in the kidneys of
27 WT and CXCR6 KO mice 4 weeks after DOCA/salt or vehicle treatment. **B.**
28 Quantitative Western blot analysis of α -SMA protein levels in the kidneys. ** $P < 0.01$
29 vs WT controls, + $P < 0.05$ vs KO-DOCA, and # $P < 0.05$ vs WT-DOCA. n=6 per group.
30



31

32

33